EXOMIND & rTMS Research Library
Researchers have studied rTMS for persistent symptoms after concussion and mild traumatic brain injury, including headache, depression and cognitive complaints. The evidence remains early.
Why this finding matters
Persistent post-concussion symptoms can disrupt work, mood, sleep and cognitive confidence. Early studies justify continued investigation, but they do not establish rTMS as a standard concussion treatment.
Research Spotlight
Early clinical evidence
- Systematic review evidence
- Small heterogeneous trials
- Post-concussion symptoms studied
- Not an established indication
What the evidence suggests
A systematic review identified clinical trials examining rTMS after concussion or mild traumatic brain injury. Some studies reported improvements in selected symptoms, but protocols and outcomes varied and the evidence base was small.
What this could mean for you
Persistent symptoms require careful assessment for neurological, psychological, sleep, pain and functional contributors. rTMS may be discussed only within a broader rehabilitation plan when clinically appropriate.
A careful, individualized next step
Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.
Start with the right clinical question
We can review the symptoms and goals to determine whether assessment, rehabilitation, psychological care or an emerging neuromodulation option is the most appropriate discussion.
Book a Consultation Explore the related Calgary service
Study citation
Mollica et al. Transcranial magnetic stimulation for the treatment of symptoms following concussion/mild traumatic brain injury. PMID: 33184973.
View the original record on PubMed
Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.